NGEN

NervGen Pharma Corp.

NASDAQ: NGEN · HEALTHCARE · BIOTECHNOLOGY

$1.59

-1.24% today

Updated 2026-07-29

Market cap

$174.52M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.46

Dividend yield

—

52W range

$2 – $6

Volume

1.1M

Market cap

$174.52M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.46

Dividend yield

—

52W range

$2 – $6

Volume

1.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

3.8

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-9.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$10.60

+566.67%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

4 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -9.40 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-8.34M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-20.54M	$-22.38M	$-23.99M	$-44.12M	$-1.70M
EPS	—	—	—	—	$-0.46
Free cash flow	$-17.65M	$-11.30M	$-16.83M	$-19.50M	$-8.34M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NGEN	$174.52M	16	4.3	3.0	5.0	3.8	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

NervGen Pharma Corp. trades at $1.59. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -9.40, it sits in the distress.

Frequently asked questions

What is NervGen Pharma Corp.'s stock price?

NervGen Pharma Corp. (NGEN) trades at $1.59.

Is NervGen Pharma Corp. overvalued?

NervGen Pharma Corp. carries a Smart Value Score of 16/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of NervGen Pharma Corp. (NGEN)?

The 12-month analyst consensus target is $10.60, about 566.7% above the current $1.59. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

NervGen Pharma Corp.'s Altman Z-Score is -9.40, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-1,207.00%

Beta0.69

50D MA$2.17

200D MA$3.51

Shares out0.11B

Float0.07B

Short ratio—

Avg volume1.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NGEN vs LLY →NGEN vs JNJ →NGEN vs ABBV →Stock screener →